惠迪对强直性脊柱炎患者外周血IFN-γ、IL-17、IL-4的影响和临床研究  

Efficacy of Huidi Mesalazine for Concentrations of in Sera IFN-γ,IL-17,IL-4 from Patients with AS Disease

作　　者：邓梅[1] 曾维国[1] 韩志伟[1] 

机构地区：[1]四川省内江市第一人民医院,四川内江641000

出　　处：《中国医学创新》2013年第10期38-39,共2页Medical Innovation of China

摘　　要：目的:探讨惠迪肠溶片对强直性脊柱炎患者外周血干扰素(IFN)-γ、白细胞介素(IL)-17、IL-4的影响,评价惠迪肠溶片治疗AS的临床疗效。方法:采用自身前后对照,纳入病例口服惠迪肠溶片,2片/次,3次/d。用ELISA的方法测定血清IFN-γ、IL-17、IL-4含量,比较用药前后的变化。结果:AS患者经惠迪肠溶片治疗后,外周血IFN-γ、IL-17的含量显著降低(P<0.05),IL-4水平改变无显著差异。结论:惠迪肠溶片能降低强直性脊柱炎患者血清IFN-γ和IL-17水平,从而抑制AS患者体内异常活跃的T细胞功能,对AS有治疗作用。Objective： To study the effects of Huidi mesalazine in patients with AS disease. Method： The concentrations of IFN-γ, IL-17, IL-4 in the sera of patients with AS disease were detected by ELISA, after the patients treated to Huidi mesalazine, compared with the self-concentration untreated. Result： The concentrations of IFN- γ, IL-17 in all patients were significantly lower, compared to the concentrations untreated （ P〈0.05 ） . The concentration of IL-4 has no significantly change. Conclusion： Huidi mesalazine can reduce the concentrations of IFN- γ, , IL-17 in the sera of patients with AS disease.

关 键 词：惠迪 强直性脊柱炎 干扰素-Γ 白细胞介素-17 白细胞介素-4 

分 类 号：R593.23[医药卫生—内科学]